Search results for: psoriasis

Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

Larry Beresford | August 6, 2021

As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

Early & Long-Term Remission of Spondyloarthritis

Jason Liebowitz, MD, FACR | July 16, 2021

Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.

Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP | June 29, 2021

In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR | June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?

Rebecca Lindsey Weiner, DO, & Ann K. Rosenthal, MD, FACP | June 14, 2021

Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…

How Immunosuppression May Affect COVID-19 Vaccine Response

Ruth Jessen Hickman, MD | June 13, 2021

Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immunosuppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

Michele B. Kaufman, PharmD, BCGP | May 28, 2021

Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.

Case Report: A Mycobacterium kansasii Infection

Kayleigh A. Sullivan, MD, MA, MPH, Nicole Orzechowski, DO, & Elizabeth A. Talbot, MD | May 13, 2021

A 61-year-old white woman presented to our rheumatology clinic in New England to establish care in early June 2018, following a move from Texas. She reported a medical history of inflammatory bowel disease, uveitis and seronegative inflammatory arthritis, which was difficult to control and required the use of multiple medications. At her initial visit, she…

Therapeutic Drug Monitoring Has Little Value During Infliximab Induction

Reuters Staff | May 12, 2021

NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…

Late Spring 2021’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel | April 17, 2021

AMA Honors Mark Andrejeski with Lifetime Achievement Award In November 2020, the American Medical Association (AMA) presented Mark Andrejeski, the recently retired executive vice president of the ACR, with its Medical Executive Lifetime Achievement Award. The award honors a medical association executive who has contributed substantially to the goals and ideals of the medical profession….